ArticleScientific reports2025
Analysis of the prevalence, spread, and mutation patterns of SARS-CoV-2 variants: data from COVID-19 testing expansion strategy study in salvador, Northeast Brazil.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
This study investigated the prevalence and genomic epidemiology of SARS-CoV-2 variants as part of the TQT-COVID-19 Project, which aimed to expand COVID-19 testing, quarantine, and telemonitoring strategies. A total of 177 samples were analyzed between July 2022 and April 2023 from patients of 17 Primary Health Care (PHC) units in Salvador, Bahia, Brazil. Sequencing was done using Oxford Nanopore MinION technology and bioinformatics analysis for variant typing and phylodynamic spread assessment. Most participants were women (68.5%), under 39 years old (48.9%), used public transportation (66.4%), had no comorbidities (66.1%), presented mild COVID-19 symptoms (40.8%), and had received a second booster dose of a COVID-19 vaccine (88.2%). Nevertheless, 11.8% had never received a COVID-19 vaccine. The most prevalent Omicron subvariants were BA.5 (32.6%), BA.4 (21.7%), B (18.8%), and BQ.1 (26.3%), with other variants like XBB also identified. Vaccinated and unvaccinated individuals had different spike gene mutations. While multiple variant introductions occurred over time, SARS-CoV-2 geographic spread was mainly localized, with occasional rapid spread associated with inter-city travel or containment failures. These findings underscore the need to track viral spread and mutations to develop targeted strategies for breaking transmission chains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.